Dendritic molecular switch: chiral folding and helicity inversion.

Appropriately designed chemical architectures can fold to adopt well-defined secondary structures without the need for structural motifs of biological origin. We have designed tris(N-salicylideneaniline)-based hyperbranched molecules that spontaneously collapse to compact three-blade propeller geometry of either (P)- or (M)-handedness. For a homologous series of compounds, a direct correlation was established between the absolute screw sense, either (P)- or (M)-, of this helical folding and the absolute configuration, either (R)- or (S)-, of the chiral alcohol groups introducing local asymmetric bias to the conformationally restricted molecular backbone.

Two-dimensional electronic conjugation: statics and dynamics at structural domains beyond molecular wires.

Chemical architectures supporting a high degree of electronic conjugation serve as important functional components in devices and materials for advanced electronic and photonic applications. Increasing the spatial dimensionality of such constructs can fundamentally modify their optoelectronic properties and significantly alter intra- and intermolecular interactions that are crucial for understanding and controlling charge/energy-transfer processes. In this article, emerging design principles in the construction of well-defined conjugated platforms beyond molecular wires are highlighted.

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.

A series of novel, potent orthopoxvirus egress inhibitors was identified during high-throughput screening of the ViroPharma small molecule collection. Using structure--activity relationship information inferred from early hits, several compounds were synthesized, and compound 14 was identified as a potent, orally bioavailable first-in-class inhibitor of orthopoxvirus egress from infected cells. Compound 14 has shown comparable efficaciousness in three murine orthopoxvirus models and has entered Phase I clinical trials.